Ocular's Axpaxli Shows Promise in Late-Stage AMD Treatment
Ocular Therapeutix recently unveiled additional encouraging data from its SOL-1 Phase 3 trial for Axpaxli, an experimental therapy aimed at treating wet age-related macular degeneration (AMD). This follows earlier results in February that did not fully align with investor forecasts. The new findings underscore the treatment's robust efficacy, highlighting its potential to significantly improve patient outcomes in this challenging retinal condition.
Breakthrough in AMD Treatment: Axpaxli's Sustained Efficacy and Reduced Disease Progression
On Monday, April 13, 2026, Ocular Therapeutix shares saw an uptick following the announcement of further positive data from the SOL-1 Phase 3 trial. The trial, designed to evaluate Axpaxli for wet age-related macular degeneration (AMD), revealed a compelling profile of durable efficacy across several critical endpoints. Axpaxli achieved statistical significance in three of the five primary secondary endpoints tested hierarchically, alongside meeting six additional pre-specified endpoints linked to meaningful functional and anatomical improvements. A post-hoc analysis brought to light Axpaxli's sustained disease control, showing a significantly reduced risk of anatomical worsening starting at Week 8 compared to patients on aflibercept. Specifically, the median time for a ≥30 µm increase in Central Subfield Thickness (CSFT) was 39 weeks for Axpaxli users versus 16 weeks for aflibercept, indicating a 23-week difference. A hazard ratio of 0.7 further suggested a 30% lower risk of worsening between Weeks 8 and 52 for Axpaxli. For more severe progression (≥75 µm CSFT increase), Axpaxli extended the median time to 46 weeks from 24 weeks, demonstrating a 50% risk reduction. Visual acuity enhancements observed during the loading phase were largely preserved through Week 52 across various baseline vision subgroups. Patients with the lowest baseline vision benefited most, gaining +11.8 ETDRS letters compared to +8.5 letters in the aflibercept group. Moreover, among patients who did not require rescue therapy, Axpaxli consistently showed stable outcomes. At Week 24, 81% of patients remained rescue-free with +7.5 letters vision gains, and 75% remained rescue-free by Week 36, maintaining most of their earlier improvements with minimal decline. The company is now preparing a New Drug Application submission, aligning with recent FDA guidance on approval processes, reinforcing Axpaxli’s potential as a competitive treatment option against existing therapies like Regeneron Pharmaceutical Inc.’s Eylea (aflibercept 2 mg).
The promising results from the Axpaxli trial offer a beacon of hope for individuals grappling with wet AMD. This development not only highlights the relentless pursuit of medical innovation in ophthalmology but also underscores the potential for new treatments to significantly enhance patients' quality of life. The sustained efficacy and reduced risk of disease progression demonstrated by Axpaxli could redefine therapeutic standards, offering longer-lasting relief and better visual outcomes. This progress reminds us of the critical importance of ongoing research and development in addressing unmet medical needs and providing advanced care for debilitating conditions.
